Dental Phobia
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Dental Phobia is an early-stage landscape with 6 programs across 2 companies. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc., McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.. 6 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Midazolam
Conrado Roberto Hoffmann Filho
Alprazolam
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Flumazenil
Conrado Roberto Hoffmann Filho
Dexmedetomidine
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)